Updated:
Arena Pharmaceuticals
Founded by Jack Lief, Arena Pharmaceuticals is a single family office investing in biotechnology and pharmaceutical companies from San Diego.
Arena Pharmaceuticals
Arena Pharmaceuticals was founded by Jack Lief in 1995 in San Diego. The firm began as a drug discovery company and later transitioned to operate as a family office managing the Lief family's wealth generated from biotech success. Lief led the company through its most notable achievement: the development of Velsipity (etrasimod), an oral S1P receptor modulator for ulcerative colitis, which received FDA approval in October 2023 and was subsequently licensed to Pfizer. The family office invests primarily in biotechnology and pharmaceutical companies, with a focus on early-stage drug development and clinical-stage assets. Arena takes a direct investment approach, co-investing alongside institutional partners in therapeutic areas including inflammation, immunology, and oncology. The firm maintains offices in San Diego, Baltimore, and Zug, Switzerland, reflecting a North American and European footprint. Confirmed portfolio investments include positions in privately held biotech firms such as Recludix Pharma and Gossamer Bio (per public filings and press releases). The firm is structured as a single family office and employs a lean team focused on proprietary deal sourcing within the life sciences sector. While total AUM and professional headcount are not publicly disclosed, the approval and licensing of Velsipity generated substantial liquidity, which the firm reinvests in new ventures. Arena does not maintain a public philanthropic foundation; its capital deployment remains concentrated on biotech and pharmaceutical direct investments. Arena's structural differentiator lies in its deep domain expertise: the principals are former biotech operators, not generalist allocators. This allows the firm to source and evaluate preclinical and clinical-stage opportunities with a scientific lens that most family offices lack. The firm does not accept outside capital, maintaining strict single-family office status.
General information
Firm type
Single Family Office
Year founded
1995
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Additional offices
Baltimore, MD, United States · Zug, Switzerland
Principals
Jack Lief
Founder & CEO (historical)
Sector focus
Frequently asked questions
Who runs investment decisions at Arena Pharmaceuticals?
Jack Lief, the founder and former CEO of Arena Pharmaceuticals, oversees the firm's investment decisions. As a family office, investment strategy is directed by the Lief family, with a focus on biotech and life sciences opportunities where the family has deep operational expertise.
How does Arena source proprietary deal flow?
Arena leverages the scientific and industry networks of its founding team, including relationships with academic institutions, contract research organizations, and former colleagues in the pharmaceutical industry. This network provides access to early-stage drug development opportunities that may not be broadly marketed.
Is Arena structured as a single family office or does it operate more like a venture firm?
Arena is a single family office. It does not manage outside capital and investment decisions are made by the Lief family. The investment approach is direct and often involves co-investment alongside institutional partners in clinical-stage biotech companies.
What investment stages does Arena typically target?
Arena invests primarily in early-stage biotechnology companies, with a focus on preclinical to clinical-stage assets. The firm targets therapeutic areas such as inflammation, immunology, and oncology, and may participate in Series A through crossover rounds.
Where does the underlying wealth come from?
The wealth was generated through the founding and operation of Arena Pharmaceuticals, a publicly traded biotech company. The key liquidity event was the FDA approval of Velsipity in October 2023 and its subsequent licensing to Pfizer, though the firm has managed the family's biotech-derived capital since its earlier years.
Does Arena maintain philanthropic structures, and how are they separated?
There is no publicly disclosed philanthropic foundation associated with Arena Pharmaceuticals. The family office appears to focus investment activities entirely on for-profit biotech and pharmaceutical ventures, without a separate charitable arm visible in public records.
What is Arena's known posture on co-investments alongside external GPs?
Arena actively co-invests alongside external institutional partners in biotech and life sciences deals. Publicly disclosed co-investments include positions in Recludix Pharma and Gossamer Bio, where Arena participated alongside venture capital firms (per SEC filings and press releases).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: